--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-257365" form_type: "8-K" ticker: "TRVI" cik: "0001563880" company_name: "Trevi Therapeutics, Inc." filed_at: "2026-06-04T20:05:16+00:00" generated_at: "2026-06-04T20:07:22.806085+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.35 calibrated_materiality_score: 0.35 confidence: "high" source: SEC EDGAR --- # Trevi Therapeutics stockholders approve doubling of authorized shares to 400M and 8M share increase in stock plan ## Summary - Elected Michael Heffernan as Class I director for a term expiring at the 2029 annual meeting. - Ratified Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026. - Advisory vote approved compensation of named executive officers with 98.1M for vs. 2.0M against. - Approved Amended and Restated 2019 Stock Incentive Plan, increasing shares available by 8M. - Approved Certificate of Amendment to double authorized common stock from 200M to 400M shares. ## SEC filing metadata - accession: 0001193125-26-257365 - form_type: 8-K - ticker: TRVI - cik: 0001563880 - company_name: Trevi Therapeutics, Inc. - filed_at: 2026-06-04T20:05:16+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.35 - calibrated_materiality_score: 0.35 - confidence: high - sec_items: 5.02, 5.03, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/0001193125-26-257365-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/trvi-20260603.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-257365 - JSON: https://secwatch.observer/filing/0001193125-26-257365.json - Plain text: https://secwatch.observer/filing/0001193125-26-257365.txt ## Key facts - Governance Changes Trevi Therapeutics, Inc.: Increased authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2026-06-03). - Change: charter amendment - Effective: 2026-06-03 source text: At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s restated certificate of incorporation (“Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock from 200,000,0000 shares to 400,000,000 shares. The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 3, 2026 evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/0001193125-26-257365-index.htm - Shareholder Votes Trevi Therapeutics, Inc. shareholders approved Election of Michael Heffernan as Class I director at the 2026-06-03 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-03 source text: Michael Heffernan was elected to the Board as a Class I director for a term expiring at the 2029 annual meeting of stockholders. For: 81,567,765 Withheld: 18,635,726 Broker Non-Votes: 14,140,404 evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/0001193125-26-257365-index.htm - Shareholder Votes Trevi Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-03 source text: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified. For: 114,001,970 Against: 223,323 Abstain: 118,602 evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/0001193125-26-257365-index.htm - Shareholder Votes Trevi Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of common stock from 200,000,000 to 400,000,000 at the 2026-06-03 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2026-06-03 source text: The Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares was approved. For: 110,453,620 Against: 3,872,599 Abstain: 17,676 evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/0001193125-26-257365-index.htm - Shareholder Votes Trevi Therapeutics, Inc. shareholders approved Approval of A&R 2019 Plan at the 2026-06-03 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-06-03 source text: The A&R 2019 Plan was approved. For: 98,140,470 Against: 1,961,030 Abstain: 101,991 Broker Non-Votes: 14,140,404 evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/0001193125-26-257365-index.htm - Shareholder Votes Trevi Therapeutics, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2026-06-03 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-03 source text: The compensation of the Company's named executive officers was approved, on an advisory basis. For: 98,119,461 Against: 1,982,126 Abstain: 101,904 Broker Non-Votes: 14,140,404 evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/0001193125-26-257365-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.